The most promising LIN28(A/B) inhibitor is C1632, which targets LIN28B + cell lines both by disruption of LIN28B–let-7 interaction (Franses et al., 2020; Zhang Q. et al., 2023; Shahab et al., 2023) and in Ewing sarcoma by disruption of the interaction between EWS-FLI1 mRNA and LIN28B (Keskin et al., 2020). The gene discussed is LIN28B; the disease is Ewing sarcoma.